Collaboration between Bio Service Provider and Biotech Company on Biospecific Cancer Antibodies

On Jan. 14, 2013, OcellO B.V., providing drug discovery screening services with its 3D cell culture-based screening platform, and Merus B.V., a biotech company, like Creative BioMart , offering specific antibodies and recombinant antibodies to help research, have entered into collaboration.

In their collaboration, OcellO will provide screening services to Merus with its 3D cell culture-based screening platform to profile bispecific antibodies designed by Merus for the treatment of cancer . Merus is good at generating many full-length, bispecific human IgG antibodies addressing combinations of targets expressed by tumor cells. And OcellO is able to provide high quality data on the functional properties of large panels of bispecific antibodies. These data can’t be obtained from other in vitro screening assays and are pivotal in identifying antibody leads with unique modes of action.

Article Link:  Collaboration between Bio Service Provider and Biotech Company on Biospecific Cancer Antibodies

Tags: OcellO and Merus,  3D Cell Culture-based Screening,  Bispecific Cancer Antibodies